查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1835554

抗药性金黄色葡萄球菌治疗市场（按给药途径、患者类型、药物类别和分销管道）—全球预测 2025-2032

Methicillin-Resistant Staphylococcus Aureus Drugs Market by Administration Route, Patient Type, Drug Class, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年抗药性金黄色葡萄球菌治疗市场将成长 37 亿美元，复合年增长率为 6.62%。

主要市场统计数据
基准年2024年 22.1亿美元
预计2025年 23.6亿美元
预测年份：2032年 37亿美元
复合年增长率（%） 6.62%

全面说明现代医疗环境中影响抗药性金黄色葡萄球菌治疗的临床、监管和卫生系统动态

抗药性金黄色葡萄球菌因其在医疗环境中引起严重感染疾病的能力以及其持续适应治疗压力的能力，一直是临床的焦点。本执行摘要提供了多方面的见解，为现代临床管理、药物开发和医疗系统应对措施提供参考。它强调了不断发展的病原体生物学、不断变化的医疗服务模式以及日益加强的监管监督如何共同影响製药、医院和公共卫生相关人员的优先事项。

引言部分围绕着治疗效果、安全性权衡以及急性住院和门诊病人医疗服务的营运现况组装讨论。报告强调了协作管理、快速诊断途径和一体化供应链韧性的必要性，同时也探讨了抗生素创新与药物开发经济学之间的相互作用。透过这样的背景，报告鼓励读者不仅了解临床需求，还了解决定新旧治疗方法的采用、指南整合和实用化的系统性槓桿。

快速诊断、新型抗生素、不断发展的监管管道和管理的整合如何重塑抗药性金黄色葡萄球菌的治疗方法

由于分子诊断技术、新型抗生素和适应性管理政策的进步，抗药性金黄色葡萄球菌的治疗方法正在经历重大变化。快速的即时诊断和近患者诊断技术能够实现更早的标靶治疗，减少经验性广效频谱的暴露，进而影响药物配方模式和下游抗药性动态。同时，新型药物和改良药物的成熟也使可用方案更加多样化，使临床医生能够在复杂的患者群体中平衡疗效和安全性。

同时，法律规范正在不断发展，以加快获取高需求抗生素的步伐，同时保持严格的安全标准，医疗卫生系统也越来越多地将抗生素管理纳入临床路径和品质指标。这些变化迫使支付者和医疗服务提供者重新评估处方安排、门诊输液治疗途径以及可能改变用药模式的家庭住院模式。因此，相关人员必须调整其商业策略、临床教育和供应物流，以满足更细緻入微、更依赖特定环境且对诊断製剂更敏感的需求。

2025年关税调整对美国基本抗生素疗法供应链策略、采购实务和取得考量的累积影响

对于依赖跨境原料药药和成品运输的製造商、经销商和医疗保健系统而言，贸易政策和关税调整已成为重要的考量。 2025年实施的关税调整正在影响整个价值链的采购成本、供应链路径和合约谈判，迫使企业重新评估筹资策略和库存缓衝。对于在海外生产特种抗菌药物及其前驱物的公司而言，这些累积的贸易成本带来了新的压力，迫使它们优化生产布局，并尽可能探索近岸外包方案。

为了应对这一变化，製造商正在重新调整供应商合同，提高到岸成本的透明度，并加快对区域产能的投资，以降低关税波动带来的风险。医院和药房正在调整采购计划和紧急时应对计画，在库存週转和紧急采购通讯协定中优先考虑关键抗生素，以保持医疗服务的连续性。重要的是，关税环境更加重视总拥有成本而非仅仅关注单位成本，鼓励製造商和大型医疗保健采购商之间采用合作合约模式，以分散风险并确保可靠地获得基本治疗。

针对给药途径、病患环境、药物类别和分销管道的详细細項分析揭示了临床定位和管道特定影响

細項分析揭示了给药途径、患者环境、特定药物所属的药物类别以及管道结构之间的重要区别，这些区别可为临床使用、商业策略和分销规划提供参考。根据给药途径的考虑，静脉注射和口服製剂之间存在差异，这会影响医院的急性护理和门诊的持续护理。这种差异会影响製剂的决策、照护和药剂师的工作流程，以及门诊肠外抗生素治疗方案的设计。

患者类型细分对比了住院和门诊病人人群，突出了治疗目标的差异：急性期快速挽救生命的干预与门诊环境中的治疗依从性、监测和安全考虑。药物类别细分包括头孢菌素类、醣肽、脂肽类、Oxazolidinone和四环素类，进一步确定了关键药物，例如醣肽类中的头孢洛林、糖肽类中的替考Teicoplanin和万古霉素、脂肽类中的Daptomycin、Oxazolidinone类中的Linezolid和泰地唑，以及四环霉素唑烷酮类中的细胞週期蛋白和泰地细胞週期蛋白。这些类别和四环霉素水平的差异揭示了临床定位、抗药性特征、不利事件监测需求以及标籤扩展和生命週期管理的潜在机会。

我们对分销管道的细分区分了医​​院、线上和零售药局管道，并重点介绍了通路选择如何影响低温运输物流、配药管理、报销机制和患者获取模式。这些细分数据相结合，提供了一个矩阵，用于将临床适应症映射到商业性管道，并协调不同医疗机构的教育、报销和供应策略。

影响美洲、欧洲、中东、非洲和亚太地区治疗采用、监管途径、采购模式和供应弹性的区域动态

区域动态持续以独特但相互关联的方式影响临床应用、监管预期和供应连续性。在美洲，医疗系统正强调快速采用符合管理规范的方案、投资门诊输液服务，以及由付款人主导的配方管理，这种管理更倾向于那些已证明具有明确安全性和营运效益的治疗方法。此外，该地区的监管格局和报销管道推动着严格的上市后和真实世界证据，附加檔和指南的纳入。

欧洲、中东和非洲的管理体制和采购模式各异，有些市场采用集中竞标，有些市场则采用分散采购。该地区的相关人员必须应对各种核准流程、新药取得途径的差异，以及在基础设施各异的国家之间分配专用抗生素的复杂性。在抗菌素抗药性监测和管理倡议方面开展区域合作，对于协调临床实践和支持跨境公共卫生应对措施正变得越来越重要。

亚太地区正经历着治疗需求的激增、医疗基础设施的快速现代化以及门诊治疗的扩张。在该地区运作的市场参与企业面临着不断变化的法规环境，都市区正在加速采用诊断主导的复合治疗方案，而农村地区则继续依赖现有的治疗方法。在不断增长的需求和加强药品自给自足的政策推动下，扩大区域製造能力和实现供应链多元化是关键主题。

主要企业如何平衡生命週期管理、新产品开发、供应链弹性和打入市场策略以应对抗药性金黄色葡萄球菌

每家公司的策略都反映了在维护核心产品系列与追求差异化创新以应对抗药性感染疾病、安全问题和门诊病人用药需求之间的平衡。领先的药物开发商会分配资源来优化现有药物的生命週期，同时投资于下一代化学型、替代製剂以及针对难治性感染疾病和併发症患者群体的临床计画。这些投资通常伴随着策略伙伴关係和许可，以缩短开发週期并扩大地域覆盖范围。

企业正在探索本地製造伙伴关係，以提高供应链透明度，确保关键投入品的多种采购管道，并降低贸易中断对区域的影响。在市场准入方面，企业专注于收集健康经济证据，参与管理项目，并将价值沟通与付款人的优先事项结合。策略差异化也体现在临床医生和药剂师的教育计画、用于门诊治疗依从性的数位化支援工具，以及旨在增强临床医生信心和支持指南考虑的上市后合作。

为製造商、付款人和医疗保健提供者提供可行的策略建议，以协调诊断、管理、製造和证据生成，以实现治疗復原力

产业领导者应优先将诊断主导的治疗途径、管理协调和供应链冗余纳入其策略规划，以保障治疗可近性和临床疗效。与诊断供应商和医疗保健系统建立更紧密的合作，可以促进合适的製剂研发，并减少不必要的广谱频谱使用。与付款人和医院系统建立伙伴关係，还可以协调有效安全治疗的奖励，降低下游成本和不良反应。同时，实现生产来源多元化并考虑区域生产基地，可以减少贸易和关税中断带来的风险，并保持关键药物供应的连续性。

在研发方面，应尽可能专注于耐受性、口服生物有效性以及支持门诊给药的剂型，以扩大临床效用，并使其更容易融入替代医疗机构。企业还应投资实用的真实世界证据项目，以证明其在常规实践中的价值，并促进灵活的报销管道。最后，积极参与管理计画、监管机构和临床协会，有助于促进指南的采纳，并确保新疗法和现有疗法的部署方式能够最大限度地造福患者，同时最大限度地减少抗药性。

一种透明的多源资讯来源调查方法，结合了临床文献综合、相关人员访谈、供应链评估和真实世界证据三角测量

本报告背后的调查方法结合了同行评审的临床文献、监管文件、公共卫生监测资料库以及对临床医生、药剂师、付款人和行业高管的结构化访谈。证据综合优先考虑高品质的实验室数据、安全报告和指南说明，以确保临床准确性，同时，来自第一线相关人员的定性见解为关于采用、物流和患者管理的实际考虑提供了参考。在适当的情况下，我们评估了真实世界证据，以便将实验室结果与日常实践联繫起来。

分析方法包括对不同给药途径和患者环境的治疗定位进行横断面评估、药物水平临床概况图谱绘製，以及专注于分销、配药和报销机制的渠道分析。透过情境分析和相关人员咨询，评估了供应链和政策影响，以了解营运部门对关税和采购变化的应对措施。在整个调查方法中，我们强调了资讯来源的透明度、对独立输入资料进行三角测量的结果，以及清晰地记录驱动解释和结论的假设。

最后，我们讨论瞭如何将治疗方法创新、综合管理和营运弹性结合起来，以维持对抗药性金黄色葡萄球菌的临床有效性。

总而言之，抗药性金黄色葡萄球菌的治疗格局正在被诊断技术、标靶治疗、适应性监管格局以及医疗服务模式的转变所重塑。这些因素正在创造机会，透过更精准的製剂改善患者预后，并透过更安全、更便利的製剂和更可靠的证据实现商业性差异化。然而，它们也对供应链敏捷性、报销参与以及与管理计划的整合提出了新的要求，以确保药物的可持续使用和持续的临床有效性。

因此，製造商、医疗系统和付款人的决策者必须采取一种整体方法，将治疗创新与实际部署考虑联繫起来，包括渠道策略、住院到门诊病人的转变、区域监管差异等。透过协调临床开发、上市计划和营运弹性，相关人员可以成功驾驭新兴市场并提供满足临床需求的治疗方法，同时降低与抗药性和供应中断相关的风险。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 提高临床实验室中用于检测 MRSA 菌株的快速分子诊断平台的整合度
  • 抗生素管理计画的增加正在推动医院对针对性抗 MRSA 治疗的需求
  • 新型β-内酰胺酶抑制剂的出现，增强了β-内酰胺类抗生素对MRSA感染疾病的疗效
  • 针对多重抗药性MRSA菌株的噬菌体疗法和协同抗生素组合的进展
  • 区域监管部门的核准加速了下一代耐甲氧西林金黄色葡萄球菌疫苗和预防药物的商业化
  • 加大对抗菌胜肽的研发投入，作为持续性抗甲氧西林金黄色葡萄球菌菌血症的替代治疗方法
  • 将人工智慧融入药物研发流程，以识别抗药性可能性较低的新型抗MRSA化合物

第六章 2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第八章抗药性金黄色葡萄球菌治疗市场（依给药途径）

  • 静脉
  • 口服

第九章抗药性金黄色葡萄球菌治疗市场（依患者型态）

  • 住院病人
  • 门诊病人

第 10 章抗药性金黄色葡萄球菌治疗市场（依药物类别）

  • 头孢菌素类
    • 头孢洛林
  • 糖肽
    • Teicoplanin
    • 万古霉素
  • 脂肽类
    • Daptomycin
  • Oxazolidinone
    • Linezolid
    • 泰地唑胺
  • 四环霉素
    • 埃拉瓦环素
    • 细胞週期蛋白

第11章抗药性金黄色葡萄球菌治疗市场（依通路）

  • 医院药房
  • 网路药局
  • 零售药局

第12章抗药性金黄色葡萄球菌治疗市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第13章抗药性金黄色葡萄球菌治疗市场（依类别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章抗药性金黄色葡萄球菌治疗市场（依国家）

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Innovation Pharmaceuticals Inc.
    • Johnson & Johnson Services, Inc.
    • AbbVie Inc.
    • Armata Pharmaceuticals, Inc.
    • AstraZeneca PLC
    • Basilea Pharmaceutica Ltd.
    • Bausch Health Companies Inc.
    • Cardinal Health, Inc.
    • Cumberland Pharmaceuticals Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Paratek Pharmaceuticals, Inc.
    • Pfizer Inc.
    • Takeda Pharmaceutical Company Limited
    • Teva Pharmaceutical Industries ltd
Product Code: MRR-0363DFE0369A

The Methicillin-Resistant Staphylococcus Aureus Drugs Market is projected to grow by USD 3.70 billion at a CAGR of 6.62% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.21 billion
Estimated Year [2025] USD 2.36 billion
Forecast Year [2032] USD 3.70 billion
CAGR (%) 6.62%

A comprehensive orientation to the clinical, regulatory, and health system dynamics shaping treatments for methicillin-resistant Staphylococcus aureus in modern care environments

Methicillin-resistant Staphylococcus aureus remains a focal point of clinical concern due to its capacity to cause severe infections across care settings and its persistent ability to adapt to therapeutic pressures. This executive summary introduces the multidimensional considerations that inform contemporary clinical management, drug development, and health system responses. It highlights how evolving pathogen biology, changing care delivery models, and intensified regulatory scrutiny converge to shape priorities across pharmaceutical, hospital, and public health stakeholders.

The introduction frames the conversation around therapeutic efficacy, safety trade-offs, and the operational realities of delivering care to both acute inpatients and ambulatory populations. It underscores the need for coordinated stewardship, faster diagnostic pathways, and integrated supply chain resilience, while also recognizing the interplay between antimicrobial innovation and the economics of drug development. By setting this context, the report primes readers to understand not only the clinical imperatives but also the systemic levers that will determine adoption, guideline incorporation, and the practical reach of novel and existing treatments.

How rapid diagnostics, emerging antibiotic classes, evolving regulatory pathways, and stewardship integration are reshaping therapeutic approaches to resistant Staphylococcus aureus

The therapeutic landscape for methicillin-resistant Staphylococcus aureus is undergoing transformative shifts driven by advances in molecular diagnostics, novel antibiotic classes, and adaptive stewardship policies. Rapid point-of-care and near-patient diagnostic technologies are reducing empirical broad-spectrum exposure by enabling earlier targeted therapy, which in turn influences prescribing patterns and downstream resistance dynamics. Simultaneously, the maturation of newer drug classes and reformulated agents has diversified available options, allowing clinicians to balance potency with safety profiles in complex patient populations.

Concurrently, regulatory frameworks are evolving to expedite access to high-need antimicrobials while maintaining rigorous safety standards, and health systems are increasingly embedding antimicrobial stewardship within clinical pathways and quality metrics. These combined shifts are prompting payers and providers to reassess formulary placement, outpatient intravenous therapy pathways, and hospital-at-home models that can alter utilization patterns. As a result, stakeholders must adapt commercial strategies, clinical education, and supply logistics to meet demand that is more nuanced, settings-driven, and sensitive to diagnostic-supported prescribing.

The cumulative effects of 2025 tariff adjustments on supply chain strategies, procurement practices, and access considerations for essential antimicrobial therapies in the United States

Trade policy and tariff adjustments have become meaningful considerations for manufacturers, distributors, and health systems that rely on cross-border active pharmaceutical ingredient flows and finished product shipments. Tariff changes implemented in 2025 impacted procurement costs, supply chain routing, and contractual negotiations across the value chain, prompting organizations to reassess sourcing strategies and inventory buffers. For companies manufacturing specialized antimicrobials or their precursors offshore, these cumulative trade costs have introduced additional pressure to optimize manufacturing footprints and to explore nearshoring options where feasible.

In response, manufacturers have been recalibrating supplier agreements, increasing transparency around landed costs, and accelerating investments in regional manufacturing capabilities to mitigate exposure to tariff volatility. Hospitals and pharmacies have adjusted procurement timelines and contingency plans to preserve continuity of care, prioritizing critical antimicrobials in stock rotation and emergency purchasing protocols. Importantly, the tariff environment has sharpened focus on total cost of ownership rather than unit price alone, encouraging collaborative contracting models between manufacturers and large healthcare purchasers to distribute risk and ensure reliable access to essential therapies.

Detailed segmentation analysis across administration routes, patient settings, drug class subtypes and distribution channels illuminating clinical positioning and channel-specific implications

Segmentation analysis reveals important distinctions that inform clinical use, commercial strategy, and distribution planning across administration route, patient setting, drug class taxonomy with specific agents identified, and channel architecture. Examination by administration route differentiates between intravenous and oral forms, with implications for hospital-based acute management and outpatient continuity of care; this dichotomy affects formulary decisions, nursing and pharmacy workflows, and the design of outpatient parenteral antimicrobial therapy programs.

Patient-type segmentation contrasts inpatient and outpatient populations, underscoring divergent therapeutic objectives: rapid, life-saving intervention in acute settings versus treatment adherence, monitoring, and safety considerations in ambulatory care. The drug class segmentation delineates cephalosporins, glycopeptides, lipopeptides, oxazolidinones, and tetracyclines, and further identifies key agents such as ceftaroline within cephalosporins; teicoplanin and vancomycin within glycopeptides; daptomycin within lipopeptides; linezolid and tedizolid within oxazolidinones; and eravacycline and tigecycline within tetracyclines. These class- and agent-level distinctions illuminate clinical positioning, resistance profiles, adverse event monitoring requirements, and potential opportunities for label expansion or life-cycle management.

Distribution channel segmentation differentiates hospital pharmacy, online pharmacy, and retail pharmacy pathways, highlighting how channel choice influences cold chain logistics, dispensing controls, reimbursement mechanisms, and patient access models. Taken together, these segmentation lenses provide a matrix for mapping clinical indications to commercial pathways and for tailoring educational, reimbursement, and supply strategies across diverse care environments.

Regional dynamics influencing therapeutic adoption, regulatory pathways, procurement models, and supply resilience across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to shape clinical adoption, regulatory expectations, and supply continuity in distinct but interrelated ways. In the Americas, health systems emphasize rapid adoption of stewardship-aligned protocols, investment in outpatient infusion services, and payer-driven formulary management that privileges therapies demonstrating clear safety and operational advantages. This region's regulatory landscape and reimbursement pathways also incentivize rigorous post-market surveillance and real-world evidence generation to support label expansion and guideline inclusion.

Europe, Middle East & Africa encompasses heterogeneous regulatory regimes and diverse procurement models, where centralized tendering in some markets contrasts with fragmented, decentralized purchasing in others. Stakeholders here must navigate varying approval timelines, differential access to novel agents, and the operational complexity of distributing specialized antimicrobials across countries with disparate infrastructure. Regional collaboration on antimicrobial resistance surveillance and stewardship initiatives is increasingly important to harmonize clinical practice and to support cross-border public health responses.

Asia-Pacific presents a mix of high-volume treatment settings, rapidly modernizing healthcare infrastructure, and expanding outpatient care delivery. Market participants operating in this region encounter variable regulatory environments and accelerating adoption of diagnostic-led prescribing in urban centers, while rural healthcare delivery continues to rely on established therapeutic regimens. Regional manufacturing capacity expansion and supply chain diversification are key themes, driven by both demand growth and policy efforts to strengthen pharmaceutical self-sufficiency.

How leading companies are balancing lifecycle management, novel development, supply chain resilience, and market access strategies to address resistant Staphylococcus aureus

Company strategies reveal a balance between preserving core product portfolios and pursuing differentiated innovations to address resistant infections, safety concerns, and outpatient administration imperatives. Leading pharmaceutical developers are allocating resources to life-cycle optimization for established agents while concurrently investing in next-generation chemotypes, alternative formulations, and clinical programs that address difficult-to-treat infections and patient populations with comorbidities. These investments are frequently accompanied by strategic partnerships and licensing arrangements aimed at accelerating development timelines and expanding geographic reach.

Commercial and manufacturing plays are equally important: firms are enhancing supply chain transparency, securing multiple sourcing pathways for critical inputs, and exploring local manufacturing partnerships to reduce regional exposure to trade disruptions. On the market access front, companies are focusing on health economic evidence generation, engagement with stewardship programs, and tailored value communication that aligns with payer priorities. Strategic differentiation also manifests through educational initiatives for clinicians and pharmacists, digital support tools for outpatient therapy adherence, and post-market surveillance collaborations that build clinician confidence and support guideline consideration.

Actionable strategic recommendations for manufacturers, payers, and providers to align diagnostics, stewardship, manufacturing, and evidence generation for therapeutic resilience

Industry leaders should prioritize integrating diagnostic-driven pathways, stewardship alignment, and supply chain redundancy into strategic planning to safeguard therapeutic access and clinical impact. Establishing closer collaboration with diagnostic vendors and health systems can accelerate appropriate prescribing and reduce unnecessary broad-spectrum use, while partnerships with payers and hospital systems can align incentives around effective, safe therapies that reduce downstream costs and adverse outcomes. Simultaneously, diversifying manufacturing sources and considering regional production hubs can mitigate exposure to trade and tariff disruptions and preserve continuity of supply for critical agents.

From a development standpoint, focusing on tolerability profiles, oral bioavailability where feasible, and formulations that support outpatient administration will expand clinical utility and ease integration into alternate care settings. Companies should also invest in pragmatic real-world evidence programs to demonstrate value in routine care and to facilitate adaptive reimbursement pathways. Finally, proactive engagement with stewardship programs, regulators, and clinical societies can help shape guideline inclusion and ensure that new and existing therapies are deployed in ways that maximize patient benefit while minimizing resistance pressure.

Transparent multi-source methodology combining clinical literature synthesis, stakeholder interviews, supply chain assessment, and real-world evidence triangulation

The research methodology underpinning this report combines a synthesis of peer-reviewed clinical literature, regulatory documentation, public health surveillance databases, and structured interviews with clinicians, pharmacists, payers, and industry executives. Evidence synthesis prioritized high-quality clinical trial data, safety reporting, and guideline statements to ensure clinical accuracy, while qualitative insights from frontline stakeholders informed practical considerations around adoption, logistics, and patient management. Where appropriate, real-world evidence sources were evaluated to contextualize trial findings in routine practice.

Analytical approaches included cross-sectional assessment of therapeutic positioning across administration route and patient setting, agent-level clinical profile mapping, and channel analysis focused on distribution, dispensing, and reimbursement mechanics. Supply chain and policy impacts were assessed through scenario analysis and stakeholder consultations to capture operational responses to tariffs and procurement shifts. Throughout, the methodology emphasized transparency of sources, triangulation of findings across independent inputs, and clear documentation of assumptions that guided interpretation and conclusions.

Concluding synthesis on how therapeutic innovation, stewardship integration, and operational resilience must converge to sustain clinical effectiveness against resistant Staphylococcus aureus

In conclusion, the landscape for methicillin-resistant Staphylococcus aureus therapies is being reshaped by concurrent advances in diagnostics, targeted therapeutics, regulatory adaptation, and changing care delivery models. These forces create opportunities for improved patient outcomes through more precise prescribing and for commercial differentiation through safer, more convenient formulations and robust evidence generation. However, they also impose new requirements for supply chain agility, reimbursement engagement, and integration with stewardship programs to ensure sustainable use and continued clinical effectiveness.

Decision-makers across manufacturers, health systems, and payers must therefore adopt a holistic approach that links therapeutic innovation to practical deployment considerations, including channel strategy, inpatient-outpatient transitions, and regional regulatory variability. By aligning clinical development, market access planning, and operational resilience, stakeholders can better navigate the evolving environment and deliver therapies that meet clinical needs while mitigating the risks associated with resistance and supply disruption.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Increasing integration of rapid molecular diagnostic platforms to detect MRSA strains in clinical laboratories
  • 5.2. Growth in antibiotic stewardship programs driving demand for targeted anti-MRSA therapeutics in hospitals
  • 5.3. Emergence of novel beta-lactamase inhibitors enhancing efficacy of beta-lactam antibiotics against MRSA infections
  • 5.4. Advances in bacteriophage therapy and synergistic antibiotic combinations targeting multi drug resistant MRSA strains
  • 5.5. Regional regulatory approvals accelerating commercialization of next generation MRSA vaccines and prophylactic agents
  • 5.6. Rising R&D investments in antimicrobial peptides as alternative treatment modalities for persistent MRSA bacteremia
  • 5.7. Integration of artificial intelligence in drug discovery workflows to identify new anti MRSA compounds with reduced resistance potential

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Administration Route

  • 8.1. Intravenous
  • 8.2. Oral

9. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Patient Type

  • 9.1. Inpatient
  • 9.2. Outpatient

10. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Drug Class

  • 10.1. Cephalosporins
    • 10.1.1. Ceftaroline
  • 10.2. Glycopeptides
    • 10.2.1. Teicoplanin
    • 10.2.2. Vancomycin
  • 10.3. Lipopeptides
    • 10.3.1. Daptomycin
  • 10.4. Oxazolidinones
    • 10.4.1. Linezolid
    • 10.4.2. Tedizolid
  • 10.5. Tetracyclines
    • 10.5.1. Eravacycline
    • 10.5.2. Tigecycline

11. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacy
  • 11.2. Online Pharmacy
  • 11.3. Retail Pharmacy

12. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Methicillin-Resistant Staphylococcus Aureus Drugs Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Innovation Pharmaceuticals Inc.
    • 15.3.2. Johnson & Johnson Services, Inc.
    • 15.3.3. AbbVie Inc.
    • 15.3.4. Armata Pharmaceuticals, Inc.
    • 15.3.5. AstraZeneca PLC
    • 15.3.6. Basilea Pharmaceutica Ltd.
    • 15.3.7. Bausch Health Companies Inc.
    • 15.3.8. Cardinal Health, Inc.
    • 15.3.9. Cumberland Pharmaceuticals Inc.
    • 15.3.10. Merck & Co., Inc.
    • 15.3.11. Novartis AG
    • 15.3.12. Paratek Pharmaceuticals, Inc.
    • 15.3.13. Pfizer Inc.
    • 15.3.14. Takeda Pharmaceutical Company Limited
    • 15.3.15. Teva Pharmaceutical Industries ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OUTPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEFTAROLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEICOPLANIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY VANCOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DAPTOMYCIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LINEZOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TEDIZOLID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ERAVACYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TIGECYCLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 146. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY CEPHALOSPORINS, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY GLYCOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY LIPOPEPTIDES, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY OXAZOLIDINONES, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY TETRACYCLINES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY PATIENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)

TABLE 253.